Ultragenyx Pharmaceutical Inc. $RARE Stock Holdings Increased by Nordea Investment Management AB

Nordea Investment Management AB grew its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 59.8% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 60,176 shares of the biopharmaceutical company’s stock after buying an additional 22,509 shares during the period. Nordea Investment Management AB owned about 0.06% of Ultragenyx Pharmaceutical worth $2,208,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. GAMMA Investing LLC lifted its stake in Ultragenyx Pharmaceutical by 76.2% during the first quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 323 shares during the last quarter. Parallel Advisors LLC lifted its position in shares of Ultragenyx Pharmaceutical by 1,061.9% in the 2nd quarter. Parallel Advisors LLC now owns 732 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 669 shares during the last quarter. ANTIPODES PARTNERS Ltd acquired a new position in shares of Ultragenyx Pharmaceutical in the 1st quarter valued at about $57,000. Headlands Technologies LLC bought a new stake in shares of Ultragenyx Pharmaceutical during the 1st quarter valued at about $59,000. Finally, Covestor Ltd raised its stake in Ultragenyx Pharmaceutical by 86.8% during the first quarter. Covestor Ltd now owns 1,711 shares of the biopharmaceutical company’s stock worth $62,000 after acquiring an additional 795 shares during the period. 97.67% of the stock is currently owned by institutional investors.

Ultragenyx Pharmaceutical Stock Performance

Shares of NASDAQ RARE opened at $33.14 on Thursday. Ultragenyx Pharmaceutical Inc. has a 52 week low of $25.81 and a 52 week high of $56.38. The firm has a market cap of $3.19 billion, a price-to-earnings ratio of -5.99 and a beta of 0.21. The business’s 50-day simple moving average is $30.55 and its 200-day simple moving average is $32.91.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) EPS for the quarter, topping analysts’ consensus estimates of ($1.27) by $0.10. The business had revenue of $166.50 million for the quarter, compared to analyst estimates of $161.37 million. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.The firm’s revenue for the quarter was up 13.2% on a year-over-year basis. During the same period in the previous year, the company posted ($1.52) earnings per share. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 2,450 shares of the business’s stock in a transaction on Friday, September 12th. The stock was sold at an average price of $31.17, for a total value of $76,366.50. Following the transaction, the executive vice president owned 73,271 shares of the company’s stock, valued at approximately $2,283,857.07. The trade was a 3.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Howard Horn sold 7,942 shares of the firm’s stock in a transaction on Monday, October 13th. The shares were sold at an average price of $31.51, for a total value of $250,252.42. Following the completion of the sale, the chief financial officer owned 98,227 shares of the company’s stock, valued at approximately $3,095,132.77. This trade represents a 7.48% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 10,456 shares of company stock worth $328,486 over the last three months. 5.50% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have commented on the company. Morgan Stanley decreased their target price on Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an “overweight” rating for the company in a research note on Monday, July 14th. Canaccord Genuity Group reduced their price objective on Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a “buy” rating for the company in a research report on Friday, August 8th. Wells Fargo & Company began coverage on Ultragenyx Pharmaceutical in a research report on Monday. They issued an “overweight” rating and a $65.00 target price on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $105.00 price target on shares of Ultragenyx Pharmaceutical in a report on Friday, September 5th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Tuesday, September 9th. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Ultragenyx Pharmaceutical has an average rating of “Moderate Buy” and a consensus price target of $82.27.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.